

Sara Hall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12163643/publications.pdf>

Version: 2024-02-01

31
papers

2,856
citations

430442

18
h-index

525886

27
g-index

32
all docs

32
docs citations

32
times ranked

4284
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. <i>JAMA Neurology</i> , 2019, 76, 1035.	4.5	455
2	Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders. <i>Archives of Neurology</i> , 2012, 69, 1445.	4.9	407
3	Blood-based NfL. <i>Neurology</i> , 2017, 88, 930-937.	1.5	369
4	Cerebrospinal fluid inflammatory markers in Parkinson's disease – Associations with depression, fatigue, and cognitive impairment. <i>Brain, Behavior, and Immunity</i> , 2013, 33, 183-189.	2.0	214
5	Non-Motor Symptoms in Patients with Parkinson's Disease – Correlations with Inflammatory Cytokines in Serum. <i>PLoS ONE</i> , 2012, 7, e47387.	1.1	180
6	CSF biomarkers and clinical progression of Parkinson disease. <i>Neurology</i> , 2015, 84, 57-63.	1.5	178
7	Levels of cerebrospinal fluid α -synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 25.	3.0	169
8	Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease. <i>Movement Disorders</i> , 2016, 31, 898-905.	2.2	136
9	Low CSF Levels of Both α -Synuclein and the α -Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy. <i>PLoS ONE</i> , 2013, 8, e53250.	1.1	123
10	Increased CSF biomarkers of angiogenesis in Parkinson disease. <i>Neurology</i> , 2015, 85, 1834-1842.	1.5	109
11	Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders. <i>Scientific Reports</i> , 2018, 8, 13276.	1.6	104
12	The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies. <i>PLoS ONE</i> , 2015, 10, e0135458.	1.1	85
13	Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease. <i>Neurobiology of Disease</i> , 2020, 139, 104831.	2.1	49
14	Proinflammatory Cytokines Are Elevated in Serum of Patients with Multiple System Atrophy. <i>PLoS ONE</i> , 2013, 8, e62354.	1.1	40
15	Disease-specific structural changes in thalamus and dentatorubrothalamic tract in progressive supranuclear palsy. <i>Neuroradiology</i> , 2015, 57, 1079-1091.	1.1	37
16	Alterations of Diffusion Kurtosis and Neurite Density Measures in Deep Grey Matter and White Matter in Parkinson's Disease. <i>PLoS ONE</i> , 2016, 11, e0157755.	1.1	35
17	Performance of α -Synuclein RT-QuIC in relation to neuropathological staging of Lewy body disease. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	2.4	31
18	Alteration of putaminal fractional anisotropy in Parkinson's disease: a longitudinal diffusion kurtosis imaging study. <i>Neuroradiology</i> , 2018, 60, 247-254.	1.1	23

#	ARTICLE	IF	CITATIONS
19	Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 63.	3.0	20
20	Diffusion Tensor MRI to Distinguish Progressive Supranuclear Palsy from α -Synucleinopathies. <i>Radiology</i> , 2019, 293, 646-653.	3.6	20
21	Low Levels of Soluble NG2 in Cerebrospinal Fluid from Patients with Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 343-350.	1.2	16
22	α 1-15/16 as a Potential Diagnostic Marker in Neurodegenerative Diseases. <i>NeuroMolecular Medicine</i> , 2013, 15, 169-179.	1.8	13
23	Differential expression of cerebrospinal fluid neuroinflammatory mediators depending on osteoarthritis pain phenotype. <i>Pain</i> , 2020, 161, 2142-2154.	2.0	11
24	Structural and functional neuroimaging changes associated with cognitive impairment and dementia in Parkinson's disease. <i>Psychiatry Research - Neuroimaging</i> , 2021, 312, 111273.	0.9	11
25	Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization. <i>Pain Reports</i> , 2022, 7, e988.	1.4	8
26	The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders. <i>Movement Disorders</i> , 2022, 37, 993-1003.	2.2	8
27	Midsagittal corpus callosal thickness and cognitive impairment in Parkinson's disease. <i>European Journal of Neuroscience</i> , 2022, 55, 1859-1872.	1.2	5
28	O4-10-01: PLASMA NFL: A NEW BIOMARKER FOR DIFFERENTIAL DIAGNOSIS OF PARKINSONIAN DISORDERS. <i>Alzheimer's and Dementia</i> , 2016, 12, P357.	0.4	0
29	P3-270: CEREBROSPINAL FLUID CONCENTRATIONS OF INFLAMMATORY MARKERS IN PARKINSON'S DISEASE AND ATYPICAL PARKINSONIAN DISORDERS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1180.	0.4	0
30	Plasma phospho-tau217 can detect Alzheimer-like pathology in Parkinson's disease with dementia and dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2020, 16, e042468.	0.4	0
31	Inflammatory, degeneration and neuritic growth biomarkers predict cognitive decline and dementia in Parkinson's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0